PROGRAM

10th INTERNATIONAL ADRENAL CANCER SYMPOSIUM

BRESCIA 2026

16TH - 18TH OCTOBER

University of Brescia, Italy

Università di Brescia

OMCeO Ordine dei Medici Chirurghi e degli Odontoiatri di Brescia

Sistema Socio Sanitario Regione Lombardia ASST Spedali Civili

10th ADRENAL CANCER SYMPOSIUM

CONGRESS CHAIRMEN

Alfredo Berruti

Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy

Massimo Terzolo

Internal Medicine, Department of Clinical and Biological Sciences, S. Luigi Gonzaga Hospital, University of Torino, Orbassano (Torino), Italy

ORGANIZING COMMITTEE

Davide Bettini, Ilaria Pedrazzini, Sara Rodella

University of Brescia, ASST Spedali Civili, Brescia, Italy

Vittoria Basile, Paola Perotti

University of Torino S. Luigi Gonzaga Hospital, Orbassano (Torino), Italy

LOCAL SCIENTIFIC COMMITTEE

Abate Andrea	Brescia	ITA
Ambrosini Roberta	Brescia	ITA
Bertagna Francesco	Brescia	ITA
Casole Giovanni	Brescia	ITA
Cosentini Deborah	Brescia	ITA
Delbarba Andrea	Brescia	ITA
Di Terlizzi Marco	Brescia	ITA
Giacchè Mara	Brescia	ITA
Grisanti Salvatore	Brescia	ITA
Laganà Marta	Brescia	ITA
Ministrini Silvia	Brescia	ITA
Pia Anna	Cuneo	ITA
Piovesan Alessandro	Asti	ITA
Poliani Luigi	Brescia	ITA
Puglisi Soraya	Orbassano	ITA
Reimondo Giuseppe	Orbassano	ITA
Sigala Sandra	Brescia	ITA
Tacchetti Maria Chiara	Brescia	ITA
Tamburello Mariangela	Brescia	ITA
Tiberio Guido	Brescia	ITA
Tinti Rita	Brescia	ITA
Volante Marco	Orbassano	ITA
Zilioli Valentina	Brescia	ITA

INTERNATIONAL SCIENTIFIC COMMITTEE

Baudin Eric	Villejuif	F
Del Rivero Jaydira	Bethesda	USA
Fassnacht Martin	Würzburg	DE
Habra Mouhammed	Riyadh	SA
Hammer Gary	Ann Arbor	USA
Lalli Enzo	Valbonne	F
Lerario Antonio Marcondes	Ann Arbor	USA
Luconi Michaela	Firenze	ITA
Ronchi Cristina	Birmingham	UK

10th ADRENAL CANCER SYMPOSIUM

FACULTY

Alberici Laura	Bologna	ITA
Albertelli Manuela	Genova	ITA
Alesina Piero	Essen	DE
Altieri Barbara	Würzburg	DE
Ambrosini Roberta	Brescia	ITA
Andreani Sara	Milano	ITA
Araujo Castro Marta	Madrid	ES
Arlt Wiebke	London	UK
Arnaldi Giorgio	Palermo	ITA
Assié Guillaume	Paris	F
Bancos Irina	Rochester	USA
Barczynski Marcin	Kraków	PL
Baudin Eric	Villejuif	F
Berruti Alfredo	Brescia	ITA
Bertherat Jerome	Paris	F
Beuschlein Felix	Zurich	CH
Bourdeau Isabelle	Montreal	CAN
Brunaud Laurent	Nancy	FR
Cannavò Salvatore	Messina	ITA
Canu Letizia	Firenze	ITA
Carling Tobias	Tampa	USA
Casali Paolo	Milano	ITA
Casole Giovanni	Brescia	ITA
Cassibba Sara	Bergamo	ITA
Ceccato Filippo	Padova	ITA
Chortis Vasileios	Birmingham	UK
Cosentini Deborah	Brescia	ITA
Crona Joakim	Uppsala	SE
De Lorenzo Francesco	Roma	ITA
Deguelte Sophie	Reims	F
Del Rivero Jaydira	Bethesda	USA
Delbarba Andrea	Brescia	ITA
Di Dalmazi Guido	Bologna	ITA
Di Maio Massimo	Torino	ITA
Dischinger Ulrich	Würzburg	DE
Engelsman Anton	Amsterdam	NL
Faron Matthieu	Villejuif	F
Fassnacht Martin	Würzburg	DE
Ferone Diego	Genova	ITA
Frisiani Guido	Milano	ITA
Garassino Marina	Chicago	USA
Giacchè Mara	Brescia	ITA
Goldmann Andrea	Winterthur	CH
Grisanti Salvatore	Brescia	ITA
Habra Mouhammed	Riyadh	SA
Hammer Gary	Ann Arbor	USA
Iacobone Maurizio	Padova	ITA
Igaz Peter	Budapest	H
Isidori Andrea	Roma	ITA
Jimenez Camilo	Houston	USA
Jouinot Anne	Paris	F
Kaltsas Gregory	Athens	GR
Kerstin Lorenz	Halle	DE
Kimpel Otilia	Würzburg	DE
Kiseljak-Vassiliades Katja	Aurora	USA
Lacroix Andrè	Montreal	CAN
Laganà Marta	Brescia	ITA
Lalli Enzo	Valbonne	F
Lamy Catherine	New York	USA
Lerario Antonio Marcondes	Ann Arbor	USA
Libè Rossella	Paris	F
Luconi Michaela	Firenze	ITA
Lugowska Iwona	Varsavia	PL
Materazzi Gabriele	Pisa	ITA
Ministrini Silvia	Brescia	ITA
Moog Sophie	Villejuif	F
Musholt Thomas J	Mainz	DE
Palazzo Fausto	London	UK
Parente Alessandro	London	UK
Peeters Robin	Rotterdam	NL
Pereira Alberto	Leiden	NL
Perera Mar Ayllon	Castellon De La Plana	ES
Pia Anna	Cuneo	ITA
Pinto Emilia	Memphis	USA
Pittaway James	London	UK
Poliani Luigi	Brescia	ITA
Puglisi Soraya	Orbassano	ITA
Raffaelli Marco	Roma	ITA
Reimondo Giuseppe	Orbassano	ITA
Ronchi Cristina	Birmingham	UK
Rossi Leonardo	Pisa	ITA
Sapienza Paolo	Roma	ITA
Sigala Sandra	Brescia	ITA
Sirianni Rosa	Rende (CS)	ITA
Stigliano Antonio	Roma	ITA
Stratakis Constantine	Athens	GR
Sutcliffe Robert	Birmingham	UK
Terzolo Massimo	Orbassano	ITA
Tiberio Guido	Brescia	ITA
Toledo Rodrigo	Barcelona	ES
Val Pierre	Clermont-Ferrand	F
Vidal Oscar	Barcellona	ES
Villar del Moral Jesus	Granada	ES
Volante Marco	Orbassano	ITA
Wiegering Verena	Würzburg	DE

10th ADRENAL CANCER SYMPOSIUM

HYBRID SESSIONS

ALL TIMES STATED IN CEST
(Central European Summer Time)

Day 1 - October 16th, 2026

1.30 - 2.00 pm		**Welcome** - Alfredo Berruti, Massimo Terzolo
2.00 - 3.00 pm		**I Session - The Added Value of European Networks for Rare Tumors** - Chairpersons: Giorgio Arnaldi, Letizia Canu, Giuseppe Reimondo
	2.00 - 2.15	ENSAT - Cristina Ronchi
	2.15 - 2.30	EURACAN - Robin Peeters
	2.30 - 2.45	ENDO-ERN - Alberto Pereira
	2.45 - 3.00	**Discussion**
3.00 - 4.30 pm		**II Session - Patient Perspectives** Chairpersons: Roberta Ambrosini, Guido Frisiani, Anna Pia
		Let's Cure ACC & Association Surrenales - Catherine Lamy
		Pheipas - Mar Ayllon Perera
		FAVO - Francesco De Lorenzo
		OECI - Iwona Lugowska
	4.30 - 5.00	Break

Day 1 - October 16th, 2026

5.00 - 6.30 pm

III Session - Proffered Papers

Chairpersons: Sara Cassibba, Filippo Ceccato, Antonio Stigliano

5.00 - 5.10

Patient-derived adrenocortical cancer organoids link molecular tumour states to individual therapeutic vulnerabilities

Van Der Vaart J.[1], Musson R.[2], De Krijger R.[3], Vietor C.[4], Dreijerink K.[5], Steenaard R.[6], Van Den Broek M.[7], Timmers H.[8], Kerstens M.[9], Haak H.[6], Langenhuijsen H.[10], Vriens M.[7], Feelders R.[4], Hofland L.[4], Maurice M.[1]

[1]Center for Molecular Medicine, UMC Utrecht, Oncode Institute, The Netherlands ~ Utrecht ~ Netherlands, [2]Central Diagnostic Laboratory, University Medical Center Utrecht, the Netherlands ~ Utrecht ~ Netherlands, [3]Princess Máxima Center for Pediatric Oncology ~ Utrecht ~ Netherlands, [4]Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center ~ Rotterdam ~ Netherlands, [5]Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam UMC, Location VUmc ~ Amsterdam ~ Netherlands, [6]Department of Internal Medicine, Máxima MC ~ Eindhoven ~ Netherlands, [7]Department of Endocrine Oncology, University Medical Center Utrecht ~ Utrecht ~ Netherlands, [8]Department of Internal Medicine, Radboud University Medical Center ~ Nijmegen ~ Netherlands, [9]Department of Endocrinology, University of Groningen, University Medical Center Groningen ~ Groningen ~ Netherlands, [10]Department of Urology, Radboud University Medical Center ~ Nijmegen ~ Netherlands

5.10 - 5.20

In vivo crispr screen identifies saga acetyltransferase activity as a therapeutic target to overcome immunotherapy resistance in adrenocortical carcinoma

Borges K.[1], Ribeiro C.[1], Chortis V.[2], Muscato A.[3], Nobrega C.[3], Wu J.[4], Xavier A.[1], Berber M.[1], Haykir B.[3], Straley K.S.[5], Antipov L.[5], Neef J.[5], Yen K.E.[5], Millan D.S.[5], Ronchi C.L.[2], Carlone D.L.[1], Yates K.[3], Manguso R.[3], Breault D.[1]

[1]Ce[1]Boston Children's Hospital - Harvard Medical School ~ Boston ~ United States of America, [2]University of Birmingham ~ Birmingham ~ United Kingdom, [3]Massachusetts General Hospital - Broad Institute ~ Boston ~ United States of America, [4]Beth Israel Deaconess Medical Center - Dana Farber Cancer Institute ~ Boston ~ United States of America, [5]Auron Therapeutics ~ Newton ~ United States of America

5.20 - 5.30

WNT5A drives immune exclusion in adrenocortical carcinoma and represents a novel immunomodulatory target

Bunker K.[1], Imodoye Y.[1], Hall J.[1], Castaneda--Hernandez G.[1], Warde K.[1], Smith L.[1], Nwariaku F.[1], Reeves M.[1], Angers S.[2], Basham K.[1]

[1]Hunstman Cancer Institute ~ Salt Lake City ~ United States of America, [2]University of Toronto ~ Toronto ~ Canada

Day 1 - October 16th, 2026

5.30 - 5.40	Personalised prediction of adjuvant mitotane survival benefit in adrenocortical carcinoma: development, external validation, and an online calculator **Saygili E.**[1], Kimpel O.[2], Laganà M.[3], Puglisi S.[4], Kastelan D.[5], Remfry J.[6], Libe R.[7], Ronchi C.[6] *[1]Faculty of Medicine, Canakkale Onsekiz Mart University, Division of Endocrinology and Metabolism, Department of Internal Medicine. ~ Canakkale ~ Turkey, [2]Division of Endocrinology and Diabetes, Department of Medicine, University Hospital, University of Würzburg. ~ Würzburg ~ Germany, [3]Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili. ~ Brescia ~ Italy, [4]Department of Clinical and Biological Sciences, Internal Medicine, San Luigi Hospital, University of Turin, Turin, Italy ~ Turin ~ Italy, [5]Department of Endocrinology, University Hospital Centre Zagreb, Zagreb, Croatia ~ Zagreb ~ Croatia, [6]Department of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham ~ Birmingham ~ United Kingdom, [7]Department of Endocrinology and National Reference Center for Rare Adrenal Disorders, AP-HP, Hôpital Cochin. ~ Paris ~ France*
5.40 - 5.50	The combined use of tyrosine kinase inhibitors and immune checkpoint inhibitor in adrenocortical carcinoma: a retrospective cohort study **Balderrama-Brondani V.**[1], Yaylaci F.[1], Marcal L.[2], Varghese J.[1], Waguespack S.G.[1], Jimenez C.[1], Shah A.Y.[3], Habra M.A.[1], Campbell M.T.[3] *[1]Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center ~ Houston ~ United States of America, [2]Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center ~ Houston ~ United States of America, [3]Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center ~ Houston ~ United States of America*
5.50 - 6.00	Hypoxia is associated with immune checkpoint expression in adrenocortical carcinoma **Kimpel O.**[1], Vékony B.[1], Uchihara M.[1], Georges C.[1], Schauer P.M.[1], Detomas M.[1], Altieri B.[2], Igaz P.[3], Fassnacht M.[1], Sbiera S.[1], *[1]Division of Endocrinology and Diabetes, Dept. of Medicine, University Hospital, University of Würzburg ~ Würzburg ~ Germany, [2]Department of Medicine and Surgery, University of Parma ~ Parma ~ Italy, [3] Department of Endocrinology, Semmelweis University ~ Budapest ~ Hungary*
6.00 - 6.10	ACC tumorminer: integrating genomics of untreated and relapsed adrenocortical carcinoma for precision oncology and DLK1-targeted therapy **Pommier Y.**, Elloumi F., Dhall A., Taniyama D., Arakawa Y., Reinhold W., Varma S., Raffeld M., Luna A., Del Rivero J. *Laboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH ~ Bethesda ~ United States of America*

Day 1 - October 16th, 2026

6.10 - 6.20	18F-CETO in adrenocortical carcinoma: first clinical-translational study of an adrenocortical-targeting pet tracer **Edholm A.***[1], Zhang L.[1], Macfarlane J.[2], Åkerström T.[1], Senanayake R.[2], Welin S.[1], Hegedus A.[1], Cheow H.[2], Lase I.[1], Stålberg P.[1], Monazzam A.[1], Gillett D.[2], Aloj L.[2], Hellman P.[1], Wargelius H.[1], Tadross J.A.[2], Antoni G.[1], Aigbirhio F.[2], Skogseid B.[1], Gurnell M.[2], Backman S.[1], Sundin A.[1], Casey R.[2], Crona J.[1] *[1]Uppsala University ~ Uppsala ~ Sweden, [2]Cambridge University ~ Cambridge ~ United Kingdom*
6.20 - 6.30	Characterization and prevalence of hereditary tumor syndrome-related adrenocortical carcinoma **Wolf K. I.***, Zheng I., Osborne J., Hammer G., Else T. *University of Michigan ~ Ann Arbor ~ United States of America*
6.30 - 6.40	A real-world, retrospective, multicenter study to evaluate the efficacy and safety of osilodrostat in patients with cortisol-secreting adrenocortical carcinoma: "The italian experience". **Aloini M.E.[1],** Lioni M.F.[1], Spagnoli A.[2], Ceccato F.[3], Canu L.[4], Locantore P.[5], Palmieri S.[6], Basile V.[7], Puglisi S.[7], Di Dalmazi G.[8], Pivonello R.[9], Berruti A.[10], Terzolo M.[7], Stigliano A.[1]
6.40 - 7.10 pm	**Keynote lecture** *Chairpersons:* Salvatore Cannavò, Salvatore Grisanti AI for Drug Discovery and Development in Immunotherapy and Targeted Therapies: Lessons from Lung Cancer Marina Garassino (University of Chicago)
7.10 - 7.45 pm	**Opening Ceremony**
7.45 - 9.00 pm	**Welcome Reception and Dinner at the Congress Venue**

10th ADRENAL CANCER SYMPOSIUM

AULA MAGNA
UNIVERSITY OF BRESCIA

ALL TIMES STATED IN CEST
(Central European Summer Time)

Day 2 - October 17th, 2026

8.30 - 10.00 am	**I Session - Molecular Heterogeneity of Adrenocortical Tumors** - *Chairpersons:* Guillaume Assié, Felix Beuschlein	
	8.30 - 8.45	Targeting the Epigenetic-Metabolic Axis: Unlocking New Therapies in ACC - Gary Hammer (University of Michigan)
	8.45 - 9.00	Clearance of senescent macrophages prevents metastatic dissemination in ACC - Pierre Val (Clermont University)
	9.00 - 9.15	Cell Fate Programs and Epigenetic Remodeling in ACC Antonio Marcondes Lerario (Ann Arbor)
	9.15 - 9.30	SF-1/NR5A1: A Master Regulator of ACC Malignancy Enzo Lalli (Institute of Molecular and Cellular Pharmacology - Valbonne)
	9.30 - 9.40	The Wnt/β-Catenin Axis: A Central Driver of ACC Progression Barbara Altieri (University of Würzburg)
	9.40 - 10.00	**Discussion**
	10.00 - 10.30	Break
10.30 am - 12.00 pm	**II Session - From Preclinical Models to Translational Research** - *Chairpersons:* Luigi Poliani, Marco Volante	
	10.30 - 10.45	Patient-Derived Models as Tools for ACC Drug Discovery Sandra Sigala (University of Brescia)
	10.45 - 11.00	Modeling Therapeutic Response: Translational Preclinical Platforms in ACC - Katja Kiseljak-Vassiliades (Colorado University - Aurora)
	11.00 - 11.15	Whole Genome Profiling in Primary and Metastatic ACC: From Biology to Clinical Prediction - Anne Jouinot (Cochin Hospital - Paris)
	11.15 - 11.30	Preclinical Immunotherapy Approaches in Pediatric ACC: Insights from TP53 p.R337H Models - Emilia Pinto (Saint Jude Hospital - Memphis)
	11.30 - 11.40	TP53 in ACC: Prognostic Value and Therapeutic Potential Isabelle Bourdeau (CHUM Research Center - Montreal)
	11.40 - 12.00	**Discussion**

Day 2 - October 17th, 2026

12.00 - 12.30 pm	**Keynote lecture** *Chairpersons:* Wiebke Arlt, Eric Baudin, Andrea Isidori Belzutifan in PPGL and VHL: A Model of Precision Oncology in Rare Tumors - Camilo Jimenez (M.D. Anderson Cancer Center - Houston)
12.30 - 1.30	Lunch & Poster Session - For details, see pages 13 - 16
1.30 - 3.00 pm	**III Session - From Bench to Bedside** *Chairpersons: Gary Hammer, Rosa Sirianni*
1.30 - 1.45	Evolution from benign to malignant adrenal lesions Constantine Stratakis (University of Athens)
1.45 - 2.00	The Microbiome–Adrenal Axis: A New Frontier in ACC Michaela Luconi (University of Firenze)
2.00 - 2.15	Unmasking DLK1: A Developmental Regulator Rewired in Adrenocortical Carcinoma and new potential target Leonardo Guasti (Queen Mary University of London)
2.15 - 2.30	Tackling Immune Resistance in ACC: Emerging Strategies Alfredo Berruti (University of Brescia)
2.30 - 2.40	Metabolic Reprogramming in ACC: Opportunities for Targeted Therapy - Vasileios Chortis (University of Birmingham)
2.40 - 3.00	**Discussion**
3.00 - 3.30	Break

Day 2 - October 17th, 2026

3.30 - 5.00 pm	**IV Session - Management of Local-Regional Disease** *Chairpersons:* Marta Araujo Castro, Maurizio Iacobone
3.30 - 3.45	R0 resection of ACC: definition and challenges Matthieu Faron (Gustave Roussy Institute - Villejuif)
3.45 - 4.00	Hyperthermic Intraperitoneal Chemotherapy: Extending Surgical Boundaries in ACC - Guido Tiberio (University of Brescia)
4.00 - 4.15	Neoadjuvant Approaches in ACC: Rationale and Clinical Evidence Rossella Libè (Cochin Hospital - Paris)
4.15 - 4.30	Adjuvant Therapy in ACC: for all, for none, for someone Massimo Terzolo (University of Torino)
4.30 - 4.45	Focus on: Optimizing Long-Term Mitotane Therapy: Strategies for Tolerability - Soraya Puglisi (University of Torino)
4.45 - 5.00	**Discussion**

Day 2 - October 17th, 2026

8.30 am- 3.00 pm	**Parallel Session - First Surgical Harmonisation Meeting on Adrenocortical Carcinoma** Looking forward a shared surgical report: technical steps for a high-quality adrenalectomy for cancer
8.30 - 10.00	Results of the Delphi rounds
10.00 - 10.30	Break
10.30 - 12.30	**Discussion of the hot topics**
	Special focus on minimally invasive adrenalectomy for ACC: laparoscopic versus robotic surgery
12.30 - 1.30	Lunch & Poster Session - For details, see pages 13 - 16
1.30 - 3.30	Voting and judgement of the final document / next steps

Laura Alberici, Piero Alesina, Sara Andreani, Marcin Barczynski, Tobias Carling, Giovanni Casole, Sophie Deguelte, Anton Engelsman, Matthieu Faron, Andrea Goldmann, Maurizio Iacobone, Lorenz Kerstin, Gabriele Materazzi, Silvia Ministrini, Thomas J Musholt, Fausto Palazzo, Alessandro Parente, Marco Raffaelli, Leonardo Rossi, Paolo Sapienza, Robert Sutcliffe, Guido Tiberio, Oscar Vidal, Jesus Villar del Moral

Day 3 - October 18th, 2026

9.00 - 10.40 am — I Session - Management of Metastatic Disease

Chairpersons: Jerome Bertherat, Mara Giacchè

9.00 - 9.15	Integrated Approaches to Advanced ACC: Combining Loco-Regional and Systemic Therapies - Jaydira Del Rivero (NIH Bethesda)
9.15 - 9.30	Is hypercortisolism a real prognostic factor? Irina Bancos (Mayo Clinic Rochester)
9.30 - 9.45	Managing Hormone Excess in Advanced ACC Gregory Kaltsas (National and Kapodistrian University of Athens)
9.45 - 10.00	Management of Advanced Pediatric Adrenocortical Carcinoma Verena Wiegering (University of Würzburg)
10.00 - 10.10	Quality of Life as a Therapeutic Goal in ACC Otilia Kimpel (University of Würzburg)
10.10 - 10.20	Defining Long-Term Responders in Metastatic ACC Deborah Cosentini (University of Brescia)
10.20 - 10.40	**Discussion**
10.40 - 11.00	Break

11.00 am - 12.20 pm — II Session - New Perspectives

Chairpersons: Joakim Crona, Marta Laganà

11.00 - 11.15	CAR-T Therapy in ACC: From Concept to Potential Clinical Impact Laura Landwehr, Martin Fassnacht (University of Würzburg)
11.15 - 11.30	Immunotherapy in ACC: Defining the Right Patient, the Right Time Mouhammed Habra (Consultant, Section of Endocrinology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia)
11.30 - 11.45	Precision Medicine in ACC: Harnessing Molecular Profiling Ulrich Dischinger (University of Würzburg)
11.45 - 11.55	Biomarkers and Predictors of Outcome in Metastatic ACC Peter Igaz (Semmelweis University of Budapest)
11.55 - 12.05	Liquid Biopsy for Real Time Monotoring of ACC Patients Rodrigo Toledo (Vall D'Hebron Institute - Barcelona)
12.05 - 12.20	**Discussion**

Day 3 - October 18th, 2026

12.20 - 12.50 pm		**Keynote lecture** *Chairpersons:* Andrea Delbarba, Diego Ferone The research on adrenal diseases: a history of successes and failures - Andrè Lacroix (University of Montreal)
	12.50 - 1.50	Lunch
1.50 - 2.50 pm		**III Session - The Challenges of Clinical Research in Rare Cancers** - *Chairpersons:* Manuela Albertelli, Guido Di Dalmazi
	1.50 - 2.05	Policy and Progress in Ultrarare Cancers Sophie Moog (Gustave Roussy Institute - Villejuif)
	2.05 - 2.20	Beyond RCTs: Innovative Trial Designs for Rare Cancers Massimo Di Maio (University of Torino)
	2.20 - 2.35	Clinical decisions in rare cancers without Phase III evidence Paolo Casali (Milano Cancer Institute)
	2.35 - 2.50	**Discussion**
2.50 - 4.30 pm		Shaping the Future of Research in ACC (Presentations and discussions of projects for future multicenter studies)
4.30 - 4.40 pm		**Closing Remarks**

10th ADRENAL CANCER SYMPOSIUM

POSTER SESSION October 17th - from 12.30 to 1.30 pm

P1	AUTOCRINE GLUCOCORTICOID SIGNALING ENABLES EFFECTIVE CAR-T CELL TARGETING IN ADVANCED ADRENOCORTICAL CARCINOMA AND OTHER SOLID CANCERS	Marc Philipp Schauer
P2	ENDOCRINE CONTROL OF TUMOR ANTIGEN PLASTICITY GOVERNS CAR-T CELL EFFICACY AND IMMUNE ESCAPE IN ADRENOCORTICAL CARCINOMA	Marc Philipp Schauer
P3	SYNERGISTIC PROGNOSTIC INTERACTION BETWEEN S-GRAS AND NEUTROPHIL-TO-LYMPHOCYTE RATIO IN HIGH-RISK ADRENOCORTICAL CARCINOMA	Erik Bényei
P4	TITLE: REAL-WORLD EXPERIENCE OF PERSONALIZED CIRCULATING TUMOR DNA (CTDNA) MONITORING USING SIGNATERA IN ADRENOCORTICAL CARCINOMA (ACC)	Yujie Zhao
P5	CASE REPORT: TRIPLE THERAPY WITH PEMBROLIZUMAB, IPILIMUMAB, AND LENVATINIB IN MITOTANE- AND RADIATION-REFRACTORY, CORTISOL-SECRETING STAGE IV ADRENOCORTICAL CARCINOMA: A GENOMICALLY GUIDED APPROACH	Afif Nakhleh
P6	GENOMIC & PHENOTYPIC CHARACTERIZATION OF BD140A: A HUMAN ADRENOCORTICAL CARCINOMA CELL LINE	Naris Nilubol
P7	TAILORED MINIMALLY INVASIVE SURGERY FOR ADRENOCORTICAL CARCINOMA - RESULTS FROM A HIGH-VOLUME ADRENALECTOMY HOSPITAL	Tobias Carling
P8	BEYOND SURGICAL LIMITS FOR A RARE DIAGNOSIS: SOMETIMES IT IS A ZEBRA AND NOT A HORSE	Giulia Carrara
P9	SURF2 IS A KEY PLAYER IN NUCLEOLAR STRESS RESPONSES, REPRESENTING A NEW THERAPEUTIC TARGET FOR ADRENOCORTICAL CARCINOMA	Manon Bongers
P10	ADRENOCORTICAL CARCINOMA, ADENOMA AND PHEOCHROMOCYTOMA IN A MOTHER–DAUGHTER PAIR DUE TO A PATHOGENIC MSH6 VARIANT	Meredith LaRue
P11	INTEGRATED STEROIDOMIC AND METABOLOMIC PROFILING BY SEMI- AND NON-POLAR COMPOUND ENRICHMENT AND LIQUID CHROMATOGRAPHY-HIGH RESOLUTION MASS SPECTROMETRY (LC-HRMS) FOR THE CHARACTERIZATION OF ADRENAL TUMORS	Greta Galante
P12	BEYOND SUVMAX: MULTIMODAL PROFILING OF ^{68}GA-DOTATOC UPTAKE AND SSTR2 IN ADRENOCORTICAL CARCINOMA	Masaki Uchihara
P13	MAST CELLS IN ADRENOCORTICAL CARCINOMA: EMERGING PLAYERS IN THE TUMOR MICROENVIRONMENT?	Grégory Menchon
P14	DEVELOPING AN SF-1 ANTAGONIST USING COMPUTATIONAL, ARTIFICIAL NEURAL NETWORK AND MACHINE LEARNING APPROACHES.	Raymond Blind
P15	AURORA: A LONGITUDINAL CLINICAL-TRANSLATIONAL MULTI-OMIC ATLAS OF ADRENOCORTICAL CARCINOMA	Emanuele Crupi
P16	ADJUVANT MITOTANE VERSUS SURVEILLANCE IN LOW-GRADE, LOCALIZED ADRENOCORTICAL CARCINOMA (ADIUVO): RESULTS OF AN EXTENDED FOLLOW-UP	Marianna Torchio
P17	ALDOSTERONE-SECRETING OLIGOMETASTATIC ADRENOCORTICAL CARCINOMA: LESSONS FROM AN N-OF-1	Alice Levine
P18	LACK OF CORRELATION OF KI-67 PROLIFERATION INDEX AND PREOPERATIVE FDG PET UPTAKE IN ADRENOCORTICAL CARCINOMA	Dana Erickson

10th ADRENAL CANCER SYMPOSIUM

POSTER SESSION October 17th - from 12.30 to 1.30 pm

P19	IN VITRO INVESTIGATION OF IGF2R-LIGAND ALL TRANS RETINOIC ACID (ATRA) IN ADRENOCORTICAL CARCINOMA (ACC).	Emma Nozza
P20	DISRUPTING CELL CYCLE CONTROL IN ADRENOCORTICAL CARCINOMA: PRECLINICAL EFFECTS OF PAN-CDKI AND PLK1I	Emanuela Esposito
P21	PRECLINICAL EVALUATION OF NIROGACESTAT IN ADRENOCORTICAL CARCINOMA: EVIDENCE FROM IN VITRO AND ZEBRAFISH XENOGRAFT MODELS	Caterina Boldini
P22	IMPROVING CLASSIFICATION OF INDETERMINATE ADRENAL INCIDENTALOMAS BY INTEGRATING IMAGING AND CLINICAL PARAMETERS	Antonio Prinzi
P23	ANDROGENS PROMOTE ANTI-TUMOR IMMUNITY IN ADRENOCORTICAL CARCINOMA THROUGH COORDINATED REGULATION OF THE ADRENAL CORTEX AND MYELOID COMPARTMENT	Kaitlin Basham
P24	TARGETING INSULIN RECEPTOR ISOFORM A IN ADRENOCORTICAL CARCINOMA: A SPLICE-SWITCHING OLIGONUCLEOTIDE APPROACH FOR PRECISION THERAPY	Sonia Di Bari
P25	ASSOCIATIONS OF PATIENT SEX AND TUMOR STEROIDOGENIC ZONATION WITH THE IMMUNE MICROENVIRONMENT IN HUMAN ADRENOCORTICAL CARCINOMA: A TRANSCRIPTOMIC ANALYSIS	Tarik Ziyad Tarik Shwaish
P26	UNVEILING KDM4B AS A CRITICAL EPIGENETIC DRIVER OF THE CIMP-HIGH AGGRESSIVE PHENOTYPE IN ADRENOCORTICAL CARCINOMA	Tarig Hamad
P27	REPROGRAMMING OF AMINO ACID METABOLISM AND POTENTIAL THERAPEUTIC RELEVANCE IN ADRENOCORTICAL CANCER.	Sheba Jarvis
P28	MITOCHONDRIAL METABOLIC REMODELLING IS ASSOCIATED WITH MITOTANE RESISTANCE IN ADRENOCORTICAL CANCER	Sheba Jarvis
P29	INTEGRATED MOLECULAR CHARACTERIZATION OF ONCOCYTIC SUBTYPE OF ADRENAL CORTICAL CARCINOMA	Marco Volante
P30	LARGE-SCALE NATIONAL EPIDEMIOLOGICAL PROFILE OF ADRENAL CARCINOMA IN BRAZIL.	Daniel Bulzico
P31	LONGITUDINAL EVALUATION OF CIRCULATING TUMOR DNA DYNAMICS IN ADRENOCORTICAL CARCINOMA AND THEIR ASSOCIATION WITH TREATMENT RESPONSE	Vania Balderrama-Brondani
P32	CONCURRENT MITOTANE AND PEMBROLIZUMAB IN ADVANCED ADRENOCORTICAL CARCINOMA: RESPONSE PATTERNS BY HISTOLOGIC SUBTYPE AND HORMONAL FUNCTION	Elio Monsour
P33	CIRCULATING TUMOR DNA AS A NONINVASIVE BIOMARKER FOR DISEASE ASSESSMENT IN ADRENOCORTICAL CARCINOMA	Vania Balderrama-Brondani
P34	SITE-SPECIFIC G0S2 PROMOTER METHYLATION AS A PROGNOSTIC BIOMARKER FOR RISK STRATIFICATION IN LOW-STAGE ADRENOCORTICAL CARCINOMA	Arianna Pia Propato
P35	DEVELOPMENT AND VALIDATION OF A NOVEL AHR REPORTER MODEL FOR THE FUNCTIONAL CHARACTERIZATION OF ARYL HYDROCARBON RECEPTOR SIGNALING IN ADRENOCORTICAL CARCINOMA.	Aurora Schiavon

POSTER SESSION October 17th - from 12.30 to 1.30 pm

P36	TARGETING CELL CYCLE REGULATORY KINASES IN PRECLINICAL MODELS OF ADRENOCORTICAL CARCINOMA	Luisa Marinoni
P37	UNIVERSAL GERMLINE GENETIC TESTING IN ADULT PATIENTS WITH ADRENOCORTICAL CARCINOMA: A SINGLE-CENTER COHORT STUDY	Florence Perreault
P38	SPLICEOSOME ALTERATION AS A NOVEL THERAPEUTIC TARGET IN ADRENOCORTICAL CARCINOMA (ACC)	Rosa Catalano
P39	ENDOFORMER: BIOLOGICALLY GROUNDED NEURO-SYMBOLIC REASONING OVER CT FOUNDATION-MODEL REPRESENTATIONS FOR ADRENOCORTICAL CARCINOMA	Ana-Silvia Corlan
P40	TARGETING THE METABOLIC-EPIGENETIC AXIS IN ADRENOCORTICAL CARCINOMA: ACETYL-COA FLUX SUSTAINS STEROIDOGENIC TUMOR IDENTITY	Johanna Werner
P41	BEYOND LI-FRAUMENI AND LYNCH SYNDROME: BROAD GERMLINE TESTING REVEALS ADDITIONAL CANCER PREDISPOSITION GENES IN ADULTS WITH ADRENOCORTICAL CARCINOMA.	Barbara Altieri
P42	IMMUNE GENE EXPRESSION SIGNATURES ARE ASSOCIATED WITH RECURRENCE IN LOCALIZED ADRENOCORTICAL CARCINOMA	Raya Leibowitz
P43	EXPLORATORY EFFECT OF ADDING SEX TO THE S-GRAS SCORE IN A SINGLE-CENTER ADRENOCORTICAL CARCINOMA COHORT.	Esther Osher
P44	CLPP AGONIST TR-107 DISRUPTS MITOCHONDRIAL FUNCTION AND STEROIDOGENESIS IN ADRENOCORTICAL CARCINOMA MODELS	George I Karadimov
P45	GERMLINE ATAXIA TELANGIECTASIA MUTATED (ATM) VARIANTS IN ADRENOCORTICAL CARCINOMA: A CASE SERIES OF THREE PATIENTS WITH AGGRESSIVE DISEASE	Florence Perreault
P46	UNMASKING ADRENOCORTICAL CARCINOMA: INITIAL PRESENTATIONS AND DIAGNOSTIC RED FLAGS – INSIGHTS FROM A LARGE SINGLE CENTER EXPERIENCE	Zuzanna Roszkowska
P47	MESENCHYMAL PHENOTYPE OF ADRENOCORTICAL CARCINOMA: A SINGLE-CELL ANALYSIS	Nano Pachuashvili
P48	PROGNOSTIC SIGNIFICANCE OF A PROGENITOR CELL-CYCLE GENE SIGNATURE IN ADRENOCORTICAL CARCINOMA: INDEPENDENT VALIDATION IN THE TCGA-ACC COHORT	Nano Pachuashvili
P49	SINGLE-CELL TRANSCRIPTOMICS REVEALS CELLULAR HETEROGENEITY AND CLONAL ARCHITECTURE IN ADRENOCORTICAL CARCINOMA	Nano Pachuashvili
P50	PATIENT-DERIVED ORGANOIDS PRESERVE THE MORPHOLOGICAL AND PROLIFERATIVE PHENOTYPE OF ADRENOCORTICAL CARCINOMA	Nano Pachuashvili
P51	ARTIFICIAL INTELLIGENCE FOR DIAGNOSIS OF ADRENAL TUMORS USING WEAKLY LABELED HISTOLOGICAL DATA	Nano Pachuashvili
P52	MANAGING MITOTANE-ASSOCIATED HEPATOTOXICITY WITH URSODEOXYCHOLIC ACID IN ADRENOCORTICAL CARCINOMA: A RETROSPECTIVE COHORT STUDY	Karolina Lisowska
P53	PRECLINICAL EVALUATION OF GLUTAMINE ANTAGONISM COMBINED WITH CYTOTOXIC CHEMOTHERAPY IN IN VITRO MODELS OF ADRENOCORTICAL CARCINOMA	Claudia Bonera

POSTER SESSION October 17th - from 12.30 to 1.30 pm

P55	CATASTROPHIC CUSHING SYNDROME DUE TO ACTH-SECRETING PHEOCHROMOCYTOMA: A DIAGNOSTIC AND THERAPEUTIC CHALLENGE	Silvia Guerini
P56	GENERATION OF AN IN-VITRO MODEL FOR THE STUDY OF HYPOXIA INDUCIBLE FACTOR IN ADRENOCORTICAL CARCINOMA CELLS	Chiara Longo
P57	DE NOVO PARENTAL GERMLINE MOSAICISM AND DIVERGENT CARCINOGENESIS IN TWINS WITH A GERMLINE TP53 P.LYS164GLU MUTATION	Svetlana Shalygina
P58	LONG-TERM DISEASE-FREE SURVIVAL FOLLOWING PATHOLOGICAL COMPLETE RESPONSE IN METASTATIC ONCOCYTIC ADRENOCORTICAL CARCINOMA	Marcin Motyka
P59	ISOLATED BRAIN RELAPSE OF PEDIATRIC ADRENOCORTICAL CARCINOMA	Joana Simões-Pereira
P60	A NOVEL CLASS OF STEROIDOGENIC FACTOR-1 (NR5A1) ANTAGONISTS: PLEIOTROPIC GENE REGULATION IN A TARGET CELL	Paul Crowe
P61	MANAGEMENT OF LIFE-THREATENING HYPERCORTISOLISM DUE TO ACTH-SECRETING PHEOCHROMOCYTOMA: A CASE REPORT	Angelo Vincenzo Cornaghi

10th ADRENAL CANCER SYMPOSIUM

GENERAL INFORMATION

CONGRESS VENUE

Aula Magna - University of Brescia - School of Medicine
Viale Europa 11 - 25123 Brescia, Italy

MEETING TIMES

ALL TIMES STATED IN CEST
(Central European Summer Time)

OFFICIAL LANGUAGE

English - no simultaneous translation

ONLINE REGISTRATION

Online registration is mandatory
Please submit your registration free of charge for the congress at
www.acc2026brescia.com

REGISTRATION

The registration is free of charge and includes:
- Coffee Break
- Lunch
- Welcome Dinner on 16th October 2026 at the Congress Venue
- Certificate of attendance

ORAGANIZING SECRETARY

ideA-Z EventsThinkers

ideA-Z Project in progress S.r.l.
Corso Giacomo Matteotti, 48 - 20081 Abbiategrasso (MI)
Ph. +39 02 9462227
Mail: info@acc2026brescia.com
Website: www.idea-z.it

10th ADRENAL CANCER SYMPOSIUM

With the unrestricted support of

PLATINUM SPONSOR

ESTEVE
Improving lives together

GOLD SPONSOR

CARLO BIANCHI tecnologie chirurgiche	Bristol Myers Squibb	Johnson&Johnson MedTech	FIRM Fondazione Internazionale di Ricerca in Medicina
Medtronic	MSD	RECORDATI RARE DISEASES Focused on the Few	Università di Brescia

Under the patronage of

AIOM ASSOCIAZIONE ITALIANA ONCOLOGIA MEDICA	AME	Sistema Socio Sanitario Regione Lombardia ASST Spedali Civili	FIRM Fondazione Internazionale di Ricerca in Medicina
OMCeO ORDINE DEI MEDICI CHIRURGHI E DEGLI ODONTOIATRI DI BRESCIA	sie Società Italiana Endocrinologia	Università di Brescia	